Aurinia Pharmaceuticals (AUPH) Downgraded by Zacks Investment Research to Sell

Aurinia Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Aurinia Pharmaceuticals Downgraded by Zacks Investment Research on 10/11/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Aurinia Pharmaceuticals (AUPH) Downgraded by Zacks Investment Research to Sell